Nanotherapeutics receives u.

Nanotherapeutics Receives U.S. Department of Defense .
http://www.centredaily.com/2010/11/03/v-print/23147.
ALACHUA, Fla. — Nanotherapeutics, Inc. announced that it has been awarded a contract bythe U.S. Department of Defense (DOD) to support a clinical trial for treating dehiscedsurgical wounds with the Company’s NanoDOX® Hydrogel, a topical doxycycline hydrogelfor chronic wounds. Nanotherapeutics is collaborating with Walter Reed Army MedicalCenter, the Henry Jackson Foundation, and the Armed Forces Institute of Pathology toconduct the trial. Funds were made available from the DOD 2009 Congressionalappropriation for the Accelerating Treatment for Trauma Wounds.
Congressman Cliff Stearns (R-FL) sponsor of the appropriation commented, “Our servicemembers in combat deserve the best medical care available and I commendNanotherapeutics for their work in developing improved treatments for chronic wounds.” The wounds sustained by combat military personnel are often traumatic and have a higherincidence of dehiscence. A dehisced wound is one that has reopened or come apart after ithas been closed surgically. An infection, injury, poor healing, or failure of the material usedto close the wound may cause wound dehiscence; the associated mortality can range from14% to 50%. Estimates are that up to 3% of civilian patients experience wound dehiscence.
The Company estimates the market at up to $3 billion annually. While NanoDOX has amilitary or biodefense application, like many of Nanotherapeutics’ products developed withfederal grants and contracts, it also has a civilian application.
NanoDOX® Hydrogel is a topical formulation of doxycycline developed by the Companyusing its proprietary particle stabilization technology. This fine particle dispersion isdesigned to improve the delivery of doxycycline and increase the local efficacy of the drug.
Nanotherapeutics has also completed a Phase lla clinical trial to evaluate the safety andefficacy of NanoDOX® Hydrogel in diabetic adults with lower extremity ulcers. The resultsof the Phase lla trial are being used to establish benchmarks for an expanded clinical trialusing NanoDOX® Hydrogel in the treatment of diabetic foot ulcers. Foot complications arethe most frequent reason for hospitalization in patients with diabetes, accounting for up to25 percent of all diabetic admissions in the United States.
NanoDOX® 1% Doxycycline Monohydrate Hydrogel
NanoDOX® Hydrogel is composed of doxycycline monohydrate, a currently marketedantibiotic available only in tablet and injectable forms. The NanoDOX® Hydrogel topical Nanotherapeutics Receives U.S. Department of Defense .
http://www.centredaily.com/2010/11/03/v-print/23147.
fine particle dispersion is applied directly to the entire surface of the wound. Gauze or anon-adhering dressing is used to cover the hydrogel and wound, providing a moist healingenvironment.
About Nanotherapeutics
Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focuson developing a diversified proprietary pipeline of products having both biodefense andmedical applications. Products under development include biodefense, CNS, woundhealing, addiction and pain, oncology, anti-infectives and orthopedics. The Company hasone FDA-approved injectable biologic NanoFUSE® DBM used by orthopedic surgeons asbone graft filler. Nanotherapeutics has in-house cGMP manufacturing, formulation, andexpertise in pre-clinical and clinical product development as well as clinical trialmanagement to support its products. Established ten years ago, the Company employsseveral proprietary platform technologies to manipulate and enhance the properties of drugcandidates. For more information, visit the Company website atwww.nanotherapeutics.com.
Have the CDT delivered to your home. Click here to subscribe.
Get the TV Book delivered to your home. Click here to subscribe.

Source: http://sidmartinbio.org/news/nanotherap_dod-contract_nanoDOX_3Nov10.pdf